Want to see PLUR full AI Analyst Report?
PLUR Stock Chart & Stats
$3.45
-$0.22(-4.74%)
At close: 4:00 PM EST
$3.45
-$0.22(-4.74%)
Day’s Range― - ―
52-Week Range$1.59 - $5.68
Previous CloseN/A
Volume1.48K
Average Volume (3M)8.39K
Market Cap
$18.50M
Enterprise Value$50.21M
Total Cash (Recent Filing)$9.55M
Total Debt (Recent Filing)$33.63M
Price to Earnings (P/E)―
Beta0.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,789,546
10 Day Avg. Volume13,380
30 Day Avg. Volume8,388
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-4.58
Price to Sales (P/S)23.48
P/FCF Ratio-1.58
Enterprise Value/Market Cap2.71
Enterprise Value/Revenue46.54
Enterprise Value/Gross Profit244.95
Enterprise Value/Ebitda-1.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.
Strategic PartnershipsStrategic partnerships expand Pluri's market reach and provide additional funding, supporting long-term growth and innovation in its product pipeline.
Leadership IncentivesAligning executive incentives with performance goals can drive strategic decision-making and improve operational efficiency, benefiting long-term company performance.
Bears Say
Financial InstabilityFinancial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.
Negative Cash FlowNegative cash flow indicates ongoing operational challenges, which may hinder Pluri's ability to sustain operations and invest in future growth without additional financing.
Profitability ChallengesOngoing profitability challenges with negative margins suggest difficulty in achieving sustainable earnings, impacting long-term financial health and investor confidence.
Pluri News
PLUR FAQ
What was Pluri’s price range in the past 12 months?
Pluri lowest stock price was $1.59 and its highest was $5.68 in the past 12 months.
What is Pluri’s market cap?
Pluri’s market cap is $18.50M.
When is Pluri’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pluri’s earnings last quarter?
Currently, no data Available
Is Pluri overvalued?
According to Wall Street analysts Pluri’s price is currently Overvalued.
Does Pluri pay dividends?
Pluri does not currently pay dividends.
What is Pluri’s EPS estimate?
Pluri’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pluri have?
Pluri has 10,789,546 shares outstanding.
What happened to Pluri’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pluri?
Currently, no hedge funds are holding shares in PLUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pluri
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Technical Analysis
Ownership Overview
7.46% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
92.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---